Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes
about
Expression of human frataxin is regulated by transcription factors SRF and TFAP2Salmonella enterica strains lacking the frataxin homolog CyaY show defects in Fe-S cluster metabolism in vivo.Hyperexpansion of GAA repeats affects post-initiation steps of FXN transcription in Friedreich's ataxiaHuman iron-sulfur cluster assembly, cellular iron homeostasis, and diseaseInfluence of Friedreich ataxia GAA noncoding repeat expansions on pre-mRNA processingFriedreich ataxia: an overviewChronochemistry in neurodegenerationIron-sulfur cluster biogenesis in mammalian cells: New insights into the molecular mechanisms of cluster deliveryUnderstanding the genetic and molecular pathogenesis of Friedreich's ataxia through animal and cellular modelsErythropoietin in Friedreich ataxiaHDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse modelCrystal structure of human frataxinCrystal structure of Escherichia coli CyaY protein reveals a previously unidentified fold for the evolutionarily conserved frataxin familyFriedreich’s Ataxia Variants I154F and W155R Diminish Frataxin-Based Activation of the Iron–Sulfur Cluster Assembly ComplexStructure–Function Analysis of Friedreich’s Ataxia Mutants Reveals Determinants of Frataxin Binding and Activation of the Fe–S Assembly ComplexYeast and human frataxin are processed to mature form in two sequential steps by the mitochondrial processing peptidase.Iron-dependent self-assembly of recombinant yeast frataxin: implications for Friedreich ataxia.CCC1 suppresses mitochondrial damage in the yeast model of Friedreich's ataxia by limiting mitochondrial iron accumulation.Mitochondrial functional interactions between frataxin and Isu1p, the iron-sulfur cluster scaffold protein, in Saccharomyces cerevisiae.Oxidative stress and the homeodynamics of iron metabolismTwo-step processing of human frataxin by mitochondrial processing peptidase. Precursor and intermediate forms are cleaved at different ratesFriedreich ataxia: from GAA triplet-repeat expansion to frataxin deficiency.Induction of oxidative metabolism by mitochondrial frataxin inhibits cancer growth: Otto Warburg revisitedFriedreich's ataxia: point mutations and clinical presentation of compound heterozygotesIron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseasesTwo new pimelic diphenylamide HDAC inhibitors induce sustained frataxin upregulation in cells from Friedreich's ataxia patients and in a mouse modelImpaired nuclear Nrf2 translocation undermines the oxidative stress response in Friedreich ataxiaThe first cellular models based on frataxin missense mutations that reproduce spontaneously the defects associated with Friedreich ataxiaA combined nucleic acid and protein analysis in Friedreich ataxia: implications for diagnosis, pathogenesis and clinical trial designOverexpression of human and fly frataxins in Drosophila provokes deleterious effects at biochemical, physiological and developmental levelsDevelopment of frataxin gene expression measures for the evaluation of experimental treatments in Friedreich's ataxiaGeneration and characterisation of Friedreich ataxia YG8R mouse fibroblast and neural stem cell modelsLymphoblast Oxidative Stress Genes as Potential Biomarkers of Disease Severity and Drug Effect in Friedreich's AtaxiaDisruption of Higher Order DNA Structures in Friedreich's Ataxia (GAA)n Repeats by PNA or LNA TargetingFrataxin is essential for extramitochondrial Fe-S cluster proteins in mammalian tissuesProlonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse modelNeurons and cardiomyocytes derived from induced pluripotent stem cells as a model for mitochondrial defects in Friedreich's ataxia.Perceived effectiveness and barriers to physical therapy services for families and children with Friedreich ataxia.Dyclonine rescues frataxin deficiency in animal models and buccal cells of patients with Friedreich's ataxia.Autosomal recessive cerebellar ataxias.
P2860
Q24298228-D4890D1D-B49B-4DE9-B746-42520BCCD834Q24537914-F90E5055-EFC7-44EC-86E4-C4E09EEB777AQ24634126-AB1AA11E-247E-42D8-ACD7-F787D4B73CC1Q24634143-850A1E9D-902D-4559-AA22-7E3D3BDFF272Q24647477-B337387E-C39A-44DC-BAD7-A49E60573DCFQ24681579-3936D9A7-AC75-4A4D-92D0-22F9600F0001Q26830057-8E50095D-7A43-4E49-B5D8-0CBCA0F9413DQ26850111-935620E0-44C6-4A4D-B0A5-768877BCCEEFQ26860523-848C82CE-8020-4A7E-8A38-5EEA65C0FFF0Q26863216-1DEB01BA-71DF-45A0-9F6E-C794EE9B0986Q27301415-E2F4C2B2-CD15-403C-9FF7-2D8DA04FE78BQ27625397-61C2C519-DB1F-4038-AD7C-AE94056EB621Q27625486-3E40F493-1873-4E2E-B929-7B6152114B15Q27670432-C1F063B8-4547-43C1-AFFF-D8856C5CEB25Q27670917-C0F9FDEF-CFCB-4BFE-8F70-C93780362012Q27932268-28DEBFA0-6493-4510-8424-5887BFFDEA37Q27934042-184234E6-5739-4616-A741-BD6E3336E365Q27935646-F6500DDF-3B25-4623-BEC6-6D5B09C2E777Q27938664-3A51630A-AE92-440C-88FD-40E864BDBF05Q28082925-51E489C9-95D1-4A81-8F13-035281F60970Q28140463-BF97948D-A029-4289-80BD-69A03F3E808BQ28200651-3286CD32-C438-4456-92DA-C83B50EAA23CQ28279921-95F6BD04-F8BD-46EC-9879-FC2C26D0E78DQ28297330-09ABC660-8932-4C67-BEE6-40AC63FA4B3CQ28388335-EEB03DDE-BE91-4DF5-AB00-F012DB5564F0Q28472583-26EDAA2F-490E-4D4F-B391-BCD49A260DF2Q28474531-404E62DC-E394-4C88-8055-73DDE336D1B4Q28475804-3378B9CC-642E-4159-BB1C-845DF706A390Q28477407-BE1CF27E-0622-4949-BD72-E3686F5933DAQ28479044-46B1F154-3CE8-4384-BD93-B6B8CB4FEF62Q28488251-6564F9E6-73B1-4A76-99AA-09C07F324459Q28540063-EBC1AECA-8C85-4D59-85F1-578468E05B97Q28551371-3F953359-9556-4F83-B89E-2CE0A570B9FFQ28553555-8021C238-5CF1-4CE0-90C0-DE00340BFF5BQ28586434-E6294C3E-71F9-4B63-8851-F17A28C26402Q28743986-BD387735-475D-4B75-9AFD-DF4E0DD6A23FQ30539140-063B004A-D45D-4C3D-A4B6-DB5E5C3FD2DCQ30540990-DAFD3030-6B99-4589-B527-763978E890B6Q30602174-D28AED9B-BA52-4198-ACD6-B9560AC486E9Q31078351-E69DC8A7-5E7B-4CDB-8F00-C983A71879F1
P2860
Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes
description
1997 nî lūn-bûn
@nan
1997 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Frataxin is reduced in Friedre ...... d with mitochondrial membranes
@ast
Frataxin is reduced in Friedre ...... d with mitochondrial membranes
@en
Frataxin is reduced in Friedre ...... d with mitochondrial membranes
@nl
type
label
Frataxin is reduced in Friedre ...... d with mitochondrial membranes
@ast
Frataxin is reduced in Friedre ...... d with mitochondrial membranes
@en
Frataxin is reduced in Friedre ...... d with mitochondrial membranes
@nl
prefLabel
Frataxin is reduced in Friedre ...... d with mitochondrial membranes
@ast
Frataxin is reduced in Friedre ...... d with mitochondrial membranes
@en
Frataxin is reduced in Friedre ...... d with mitochondrial membranes
@nl
P2093
P2860
P50
P3181
P356
P1476
Frataxin is reduced in Friedre ...... d with mitochondrial membranes
@en
P2093
B Faucheux
C Hindelang
F J Authier
L Montermini
M Pandolfo
S Jiralerspong
P2860
P304
P3181
P356
10.1093/HMG/6.11.1771
P407
P577
1997-10-01T00:00:00Z